Paolo Pedrazzoli

Summary

Affiliation: Niguarda Hospital
Country: Italy

Publications

  1. ncbi Transplantation of allogeneic hematopoietic stem cells: an emerging treatment modality for solid tumors
    Taner Demirer
    Department of Haematology Oncology, Ankara University Medical School, Turkey
    Nat Clin Pract Oncol 5:256-67. 2008
  2. ncbi Treatment of metastatic neuroendocrine carcinomas based on WHO classification
    Salvatore Artale
    Ospedale Niguarda Ca Granda, Piazza Ospedale Maggiore 3, 1 20162 Milan, Italy
    Anticancer Res 25:4463-9. 2005
  3. ncbi Pegfilgrastim: current and future perspectives in the treatment of chemotherapy-induced neutropenia
    Riccardo Ricotta
    Ospedale Niguarda Ca Granda, Piazza Ospedale Maggiore 3, 20162 Milano, Italy
    Future Oncol 2:667-76. 2006
  4. ncbi Iron supplementation and erythropoiesis-stimulatory agents in the treatment of cancer anemia
    Paolo Pedrazzoli
    The Falck Division of Medical Oncology, Niguarda Ca Granda Hospital, Milan, Italy
    Cancer 115:1169-73. 2009
  5. ncbi Randomized trial of intravenous iron supplementation in patients with chemotherapy-related anemia without iron deficiency treated with darbepoetin alpha
    Paolo Pedrazzoli
    Divisione di Oncologia Medica Falck, Ospedale Niguarda Ca Granda, Piazza Ospedale Maggiore 20162, Milano, Italy
    J Clin Oncol 26:1619-25. 2008
  6. ncbi High dose chemotherapy with autologous hematopoietic stem cell support for solid tumors other than breast cancer in adults
    P Pedrazzoli
    Falck Division of Medical Oncology, Ospedale Niguarda Ca Granda, Milano, Italy
    Ann Oncol 17:1479-88. 2006
  7. ncbi High-dose chemotherapy with autologous hematopoietic stem cell support for solid tumors in adults
    Paolo Pedrazzoli
    Divisione di Oncologia Medica Falck, Ospedale Niguarda Ca Granda, Milano, Italy, and Department of Hematology, Ankara University Medical School, Turkey
    Semin Hematol 44:286-95. 2007
  8. ncbi Reduced intensity stem cell transplantation for advanced soft tissue sarcomas in adults: a retrospective analysis of the European Group for Blood and Marrow Transplantation
    Simona Secondino
    Divisione Oncologica Falck, Ospedale Niguarda Ca Granda, Milan, Italy
    Haematologica 92:418-20. 2007
  9. ncbi Percutaneous vertebral augmentation in metastatic disease: state of the art
    Flavio Tancioni
    Department of Neurosurgery, Istituto Clinico Humanitas, Milan, Italy
    J Support Oncol 9:4-10. 2011
  10. ncbi Iron supplementation during treatment with erythropoiesis-stimulating agents for cancer-related anemia
    Ilaria Schiavetto
    Oncologia Medica Falck, Ospedale Niguarda Ca Granda, Milano, Italy
    Chemotherapy 54:417-20. 2008

Detail Information

Publications28

  1. ncbi Transplantation of allogeneic hematopoietic stem cells: an emerging treatment modality for solid tumors
    Taner Demirer
    Department of Haematology Oncology, Ankara University Medical School, Turkey
    Nat Clin Pract Oncol 5:256-67. 2008
    ..Targeted therapies may complement the immune effect of allogeneic transplantation. We present updated results from the literature and data recently placed on file at the European Bone Marrow Transplantation Solid Tumors Working Party...
  2. ncbi Treatment of metastatic neuroendocrine carcinomas based on WHO classification
    Salvatore Artale
    Ospedale Niguarda Ca Granda, Piazza Ospedale Maggiore 3, 1 20162 Milan, Italy
    Anticancer Res 25:4463-9. 2005
    ..Grade 3-4 side-effects were limited to 9% thrombocytopenia and 12.5% neutropenia. Both these treatment regimens had a good therapeutic index and compared favourably with those previously reported for metastatic WD-NECs and PD-NECs...
  3. ncbi Pegfilgrastim: current and future perspectives in the treatment of chemotherapy-induced neutropenia
    Riccardo Ricotta
    Ospedale Niguarda Ca Granda, Piazza Ospedale Maggiore 3, 20162 Milano, Italy
    Future Oncol 2:667-76. 2006
    ..Recent trials have been conducted to evaluate the use of pegfilgrastim in different clinical settings, including support of dose-dense regimens, mobilization and transplantation of hematopoietic stem cells...
  4. ncbi Iron supplementation and erythropoiesis-stimulatory agents in the treatment of cancer anemia
    Paolo Pedrazzoli
    The Falck Division of Medical Oncology, Niguarda Ca Granda Hospital, Milan, Italy
    Cancer 115:1169-73. 2009
    ..In this article, the authors discuss the role of iron supplementation in the setting of CRA in view of recent reports that have addressed this issue...
  5. ncbi Randomized trial of intravenous iron supplementation in patients with chemotherapy-related anemia without iron deficiency treated with darbepoetin alpha
    Paolo Pedrazzoli
    Divisione di Oncologia Medica Falck, Ospedale Niguarda Ca Granda, Piazza Ospedale Maggiore 20162, Milano, Italy
    J Clin Oncol 26:1619-25. 2008
    ..We have prospectively evaluated whether intravenous iron can increase the proportion of patients with chemotherapy-related anemia who respond to darbepoetin...
  6. ncbi High dose chemotherapy with autologous hematopoietic stem cell support for solid tumors other than breast cancer in adults
    P Pedrazzoli
    Falck Division of Medical Oncology, Ospedale Niguarda Ca Granda, Milano, Italy
    Ann Oncol 17:1479-88. 2006
    ..In this article, we critically review and comment on the data from studies of high dose chemotherapy so far reported in adult patients with small cell lung cancer, ovarian cancer, germ cell tumors and sarcomas...
  7. ncbi High-dose chemotherapy with autologous hematopoietic stem cell support for solid tumors in adults
    Paolo Pedrazzoli
    Divisione di Oncologia Medica Falck, Ospedale Niguarda Ca Granda, Milano, Italy, and Department of Hematology, Ankara University Medical School, Turkey
    Semin Hematol 44:286-95. 2007
    ..In this article, we review and comment on the data from studies to date of HDC for solid tumors in adults...
  8. ncbi Reduced intensity stem cell transplantation for advanced soft tissue sarcomas in adults: a retrospective analysis of the European Group for Blood and Marrow Transplantation
    Simona Secondino
    Divisione Oncologica Falck, Ospedale Niguarda Ca Granda, Milan, Italy
    Haematologica 92:418-20. 2007
    ..Our study may suggest that an immune-mediated effect cannot be excluded in some STS...
  9. ncbi Percutaneous vertebral augmentation in metastatic disease: state of the art
    Flavio Tancioni
    Department of Neurosurgery, Istituto Clinico Humanitas, Milan, Italy
    J Support Oncol 9:4-10. 2011
    ....
  10. ncbi Iron supplementation during treatment with erythropoiesis-stimulating agents for cancer-related anemia
    Ilaria Schiavetto
    Oncologia Medica Falck, Ospedale Niguarda Ca Granda, Milano, Italy
    Chemotherapy 54:417-20. 2008
    ..In this article, we review and discuss the role of iron supplementation in the setting of chemotherapy-related anemia in view of recently published clinical trials addressing this issue...
  11. ncbi Darbepoetin alpha coming of age
    Paolo Pedrazzoli
    Falck Medical Oncology Unit, Niguarda Ca Granda Hospital, Milano, Italy
    Anticancer Res 27:4419-24. 2007
    ..However, it is also clear from recent reports that scrutiny on the safe use of these drugs is still required...
  12. ncbi Optimising management of neutropenia and anaemia in cancer chemotherapy-advances in cytokine therapy
    Salvatore Siena
    Dipartimento di Oncologia ad Ematologia, Ospedale Niguarda Ca Granda, Piazza Ospedale Maggiore 3, I 20162 Milan, Italy
    Crit Rev Oncol Hematol 48:S39-47. 2003
    ..These novel cytokines have the potential to simplify the management of neutropenia and anaemia with fewer injections and less disruption to patients daily lives...
  13. ncbi Prognostic factors for survival in patients with advanced renal cell carcinoma undergoing nonmyeloablative allogeneic stem cell transplantation
    Jacopo Peccatori
    Hematology-Bone Marrow Transplant Unit, Istituto Scientifico H. San Raffaele, Milano, Italy
    Cancer 104:2099-103. 2005
    ....
  14. ncbi Allogeneic blood stem cell transplantation after a reduced-intensity, preparative regimen: a pilot study in patients with refractory malignancies
    Paolo Pedrazzoli
    Divisione di Oncologia Medica Falck, Ospedale Niguarda Ca Granda, Milano, Italy
    Cancer 94:2409-15. 2002
    ..The objectives of the current study were to evaluate the feasibility of this approach in terms of toxicity and engraftment and to document evidence of GVT effects...
  15. ncbi Therapeutic targeting of epidermal growth factor receptor with monoclonal antibodies
    Salvatore Siena
    Falck Division of Medical Oncology, Department of Oncology and Hematology, Niguarda Ca' Granda Hospital, Milan, Italy
    Suppl Tumori 1:S46-8. 2002
  16. ncbi Autologous hematopoietic stem cell transplantation for breast cancer in Europe: critical evaluation of data from the European Group for Blood and Marrow Transplantation (EBMT) Registry 1990-1999
    P Pedrazzoli
    S C Divisione di Oncologia Medica Falck, Ospedale Niguarda Ca Granda, Milano, Italy
    Bone Marrow Transplant 32:489-94. 2003
    ..Outcome of patients with IBC is encouraging, suggesting the need for randomized trials. Patients with metastatic disease responding to pretransplant chemotherapy and harboring ER+ tumors have a better outcome...
  17. ncbi Present results and perspectives of allogeneic non-myeloablative hematopoietic stem cell transplantation for treatment of human solid tumors
    M Renga
    Divisione Oncologia Medica Falck, Dipartimento di Oncologia ed Ematologia, Ospedale Niguarda Ca Granda, Milan, Italy
    Ann Oncol 14:1177-84. 2003
    ..In the present article we review the biological basis, development and early clinical results of this novel immunotherapeutic approach for solid tumors...
  18. ncbi High dose chemotherapy and hematopoietic progenitor cell transplantation for breast cancer
    P Pedrazzoli
    SC Oncologia Medica Falck, Dipartimento Oncologico, Ospedale Niguarda Ca Granda, 1 20162 Milano, Italy
    J Chemother 16:108-11. 2004
    ..They also discuss what may be the attitude to take in our everyday clinical practice, taking into account the availability of new chemotherapeutic agents and targeted therapies...
  19. ncbi Neuroimaging abnormalities in adult medulloblastoma undergoing intensified therapy
    Simona Secondino
    Oncologia Medica Falck, Ospedale Niguarda Ca Granda, 20162 Milano, Italy
    Anticancer Res 28:3991-2. 2008
    ....
  20. ncbi Therapeutic relevance of CD34 cell dose in blood cell transplantation for cancer therapy
    S Siena
    Falck Division of Medical Oncology, Department of Hematology and Oncology, Ospedale Niguarda Ca Granda, Milan, Italy
    J Clin Oncol 18:1360-77. 2000
    ..To review recent advances in peripheral-blood progenitor-cell (PBPC) transplantation in order to define the optimal cell dose required for autologous and allogeneic transplantation...
  21. ncbi Multimodal approach to the management of metastatic epidural spinal cord compression (MESCC) due to solid tumors
    Flavio Tancioni
    Department of Neurosurgery, Istituto Clinico Humanitas, Milan, Italy
    Int J Radiat Oncol Biol Phys 78:1467-73. 2010
    ..To assess the impact of a multidisciplinary approach for treatment of patients with metastatic epidural spinal cord compression in terms of feasibility, local control, and survival...
  22. ncbi Establishment and characterization of a new Ewing's sarcoma cell line from a malignant pleural effusion
    Roberta Schiavo
    Falck Division of Medical Oncology, Ospedale Niguarda Ca Granda, Milan, Italy
    Anticancer Res 27:3273-8. 2007
    ..In the present study, we report the establishment and characterization of a primary Ewing's sarcoma cell line (LDS-Falck 01)...
  23. ncbi Survival of adults treated for medulloblastoma using paediatric protocols
    Filippo Spreafico
    Paediatric Unit, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan, Italy
    Eur J Cancer 41:1304-10. 2005
    ....
  24. ncbi GMP production of anti-tumor cytotoxic T-cell lines for adoptive T-cell therapy in patients with solid neoplasia
    I Turin
    Immunology Laboratory and Pediatric Hematology Oncology, IRCCS Policlinico San Matteo, Milan, Italy
    Cytotherapy 9:499-507. 2007
    ..We have now investigated the possibility of producing large amounts of autologous anti-tumor CTL, in compliance with good manufacturing practices, for in vivo use...
  25. ncbi Iron supplement in cancer patients receiving erythropoietin
    Paolo Pedrazzoli
    J Clin Oncol 22:4428; author reply 4428-9. 2004
  26. ncbi Germ-cell tumors
    Ugo De Giorgi
    N Engl J Med 357:1773; author reply 1773-4. 2007
  27. ncbi Ex vivo generation and expansion of anti-tumor cytotoxic T-cell lines derived from patients or their HLA-identical sibling
    Daniela Montagna
    Immunology Laboratory and Pediatric Hematology Oncology, IRCCS Policlinico San Matteo, University of Pavia, Piazzale Golgi, 27100 Pavia, Italy
    Int J Cancer 110:76-86. 2004
    ..Altogether these results demonstrate that our experimental approach is suitable for efficiently generating and expanding anti-solid tumor CTL to be used for adoptive immunotherapy...
  28. ncbi Cell therapy of stage IV nasopharyngeal carcinoma with autologous Epstein-Barr virus-targeted cytotoxic T lymphocytes
    Patrizia Comoli
    Laboratorio di Ricerca Area Trapianti e Oncoematologia Pediatrica, IRCCS Policlinico S Matteo, V le Golgi 19, 27100 Pavia, Italy
    J Clin Oncol 23:8942-9. 2005
    ..We conducted a clinical trial of EBV-targeted cell therapy with autologous virus-specific cytotoxic T lymphocytes (CTLs) for NPC refractory to conventional treatments...